Corvus Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 10.23 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 860.56M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferat...